Skip to content

Electrotherapy in the treatment of pain during intercourse and assessment of the outcomes on the quality of life and sexuality of women with deep endometriosis

Transcutaneous Electrical Nerve Stimulation (TENS) in the treatment of deep dyspareunia and assessment of the impact on the quality of life and sexuality of women with deep endometriosis: randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-3rndh6
Enrollment
Unknown
Registered
2014-07-07
Start date
2013-10-25
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis. Dyspareunia.

Interventions

Group 1: 20 women with endometriosis will receive aplications of Conventional Transcutaneous Electrical Nerve Stimulation (TENS)(Quark), once a week, for 30 minutes, during 8 weeks, in the sacral regi
Device

Sponsors

Ticiana Aparecida Alves de Mira
Lead Sponsor
Ticiana Aparecida Alves de Mira
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Sexually active women. Women in menacme. Diagnosis of endometriosis estages III, IV and/or of the rectovaginal septum. Deep dyspareunia.

Exclusion criteria

Exclusion criteria: Decreased skin sensitivity preventing the perception of the electric stimulus. Pregnant women. Pacemaker users. Hypersensitivity (allergic reactions to the gel or electrode). Epilepsy. Heart disease (arrhythmia). Osteosynthesis at the application site. Open sores. Malignant tumors. Acute inflammatory disease. Other associated gynecological pathologies. Cognitive disabilities that prevente the understanding of the use of the tools and/or conventional electrotherapeutic treatment or do not understand instructions for the use of the self-applied TENS.

Design outcomes

Primary

MeasureTime frame
Deep dyspareunia relief and/or resolution analyzed through the visual analogue scale from the variance observed at least 5% of the pre and post treatment results.

Secondary

MeasureTime frame
Improvement at quality of life measured through a whoqol-bref quality of life questionnaire plus an endometriosis quality of life questionnaire from observations of 5% significance in the pre and post treatment results.;Sexuality improvement measured through the Female Sexual Function Index from observations of 5% significance in the pre and post treatment results.

Countries

Brazil

Contacts

Public ContactTiciana Mira

Universidade Estadual de Campinas

ticiana.mira@gmail.com+55 (19)3521-9333

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Mar 15, 2026